ACADIA Pharmaceuticals Inc (NAS:ACAD)
$ 16.95 -0.42 (-2.42%) Market Cap: 2.89 Bil Enterprise Value: 2.37 Bil PE Ratio: 22.27 PB Ratio: 5.01 GF Score: 75/100

ACADIA Pharmaceuticals Inc at Citi BioPharma Conference Transcript

Sep 08, 2022 / 05:00PM GMT
Release Date Price: $17.42 (+3.38%)
Neena Marie Bitritto;Garg
Citigroup Inc., Research Division - VP & Analyst

All right. Well, hi, everyone. Thank you so much for taking the time to join Citi's Annual Biopharma Conference. I am Neena Bitritto-Garg, one of the biotech analysts here at Citi. I'm very pleased to be joined for our next fireside chat by the management team from ACADIA Pharmaceuticals. So I have with me the company's CEO, Steve Davis, my company's CFO, Mark.

Questions & Answers

Neena Marie Bitritto;Garg
Citigroup Inc., Research Division - VP & Analyst

We're actually going to jump directly into Q&A. (Operator Instructions) But I just want to start off with a general question on capital allocation and how you're thinking about that just after the pimavanserin ADP, PDUFA. How should we think about kind of relative prioritization between the commercial franchise with pimavanserin, the R&D pipeline? And recently, I know you've talked a lot about external -- kind of looking at external opportunities, given the market dynamics

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot